Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed the BSE that the SEBI Regulation 32(1) requirement to file a Statement of Deviation or Variation does not apply to the company for the quarter and full year ended 31 March 2025. This is because the company did not undertake any public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP) during the period — so there are no proceeds of a fund-raising exercise to report deviations or variations on. The filing was submitted in letter format because the XBRL system does not allow a NIL entry. The letter is signed by Dr K Koteswara Rao, Chairman & Managing Director.
This is a routine, neutral compliance disclosure with no material effect on the business or shareholders. It simply confirms the company did not raise funds through public market issues in Q4 or FY25, meaning there is no new dilution or capital-raising event to evaluate.